Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
Published on: July 12, 2024
Best Practices in Fragile X Syndrome Treatment Development
Craig A Erickson1,2, Walter E Kaufmann3,4, Dejan B Budimirovic5,6
1Division of Child & Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. craig.erickson@cchmc.org.
Abstract:
Preclinical studies using animal models of fragile X syndrome have yielded several agents that rescue a wide variety of phenotypes. However, translation of these treatments to humans with the disorder has not yet been successful, shedding light on a variety of limitations with both animal models and human trial design. As members of the Clinical Trials Committee of the National Fragile X Foundation, we have discussed a variety of recommendations at the level of preclinical development, transition from preclinical to human projects, family involvement, and multi-site trial planning. Our recommendations are made with the vision that effective new treatment will lie at the intersection of innovation, rigorous and reproducible research, and stakeholder involvement.
Insights
Fragile X syndrome treatments show promise in animal models but face translation challenges in humans. Recommendations focus on improving preclinical studies, human trials, and stakeholder engagement for effective therapies.
Area of Science:
- Neuroscience
- Genetics
- Clinical Trials
Background:
- Preclinical studies in animal models of fragile X syndrome (FXS) have identified potential therapeutic agents.
- Translating these findings to human treatments for FXS has proven challenging due to limitations in current models and trial designs.
Purpose of the Study:
- To discuss and provide recommendations for improving the development and translation of FXS treatments.
- To address limitations in preclinical research, human trial design, and stakeholder involvement.
Main Methods:
- Recommendations developed by the Clinical Trials Committee of the National Fragile X Foundation.
- Discussion focused on preclinical development, transition to human studies, family engagement, and multi-site trial planning.
Main Results:
- Identified limitations in the translation of preclinical findings to human therapies for FXS.
- Proposed a framework for enhancing the rigor and reproducibility of research and clinical trials.
Conclusions:
- Effective treatments for FXS require innovation, robust research, and active stakeholder involvement.
- Recommendations aim to bridge the gap between preclinical discoveries and successful human therapeutic interventions for FXS.
More Related Videos
Related Concept Videos
Sustainable Development
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
Equivalent Circuits for Practical Transformers
In a practical transformer, each winding exhibits resistance and leakage reactance. The...
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction

